3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
2
Phase EARLY_PHASE1
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Breast Neoplasms
3
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Sarcoma, Clear Cell
1
Rectal Neoplasms
1
Radiation-induced Oral Mucositis
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Platinum-resistant Epithelial Ovarian Cancer
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms, Male
1
Anatomic Stage I Breast Cancer AJCC v8
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
74
Nivolumab
53
Ipilimumab
42
Cyclophosphamide
32
Interleukin-2
24
aldesleukin
23
Temozolomide
17
fludarabine
16
Biopsy
11
trametinib
10
fludarabine phosphate
10
dabrafenib
10
spartalizumab
8
Paclitaxel
8
Dacarbazine
8
sargramostim
7
cemiplimab
7
binimetinib
7
Cisplatin
7
Bevacizumab
7
poly ICLC
6
lenvatinib
6
epacadostat
6
Radiotherapy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
encorafenib
5
atezolizumab
5
Vemurafenib
5
Specimen Handling
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Melanoma
×
Hydroxychloroquine
×
Clear all
NCT04464759
2026-05-11
LIMIT
Abramson Cancer Center at Penn Medicine
Phase 1/2
Recruiting
94 enrolled
NCT03754179
2021-04-28
COMBI-R2
Universitair Ziekenhuis Brussel
Phase 1/2
Unknown
63 enrolled